Payment overview · 2025
General Payments
$256.52
15 reported records · 12 companies
Healthcare provider profile · identity verified
Mallory Haas, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · HOLDREGE, NE · NPI 1447617949
Verified facts
What the public records show
CMS Open Payments records show Mallory Haas, PA-C received $256.52 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.17 | 14.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.25 | 13.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.18 | 13.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.65 | 12.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.46 | 7.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.65 | 7.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.27 | 6.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.28 | 6.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.74 | 5.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.31 | 5.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.82 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.74 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.52 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.25 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.18 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
185 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 712 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 514 | 91 |
| Omeprazole | Omeprazole | 458 | 95 |
| Losartan Potassium | Losartan Potassium | 389 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 376 | 65 |
| Potassium Chloride | Potassium Chloride | 370 | 60 |
| Montelukast Sodium | Montelukast Sodium | 350 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 308 | 59 |
| Furosemide | Furosemide | 259 | 44 |
| Lisinopril | Lisinopril | 257 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 236 | 73 |
| Famotidine | Famotidine | 231 | 34 |
| Gabapentin | Gabapentin | 210 | 37 |
| Ezetimibe | Ezetimibe | 202 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 194 | 38 |
| Eliquis | Apixaban | 185 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 182 | 27 |
| Meloxicam | Meloxicam | 180 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 173 | 25 |
| Simvastatin | Simvastatin | 156 | 32 |
| Carvedilol | Carvedilol | 151 | 24 |
| Metformin Hcl Er | Metformin Hcl | 151 | 28 |
| Trazodone Hcl | Trazodone Hcl | 151 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 47 |
| Allopurinol | Allopurinol | 142 | 19 |
| Prednisone | Prednisone | 141 | 70 |
| Tramadol Hcl | Tramadol Hcl | 141 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 14 |
| Jardiance | Empagliflozin | 133 | 18 |
| Metformin Hcl | Metformin Hcl | 130 | 21 |
| Spironolactone | Spironolactone | 130 | 25 |
| Warfarin Sodium | Warfarin Sodium | 130 | 17 |
| Sertraline Hcl | Sertraline Hcl | 129 | 20 |
| Donepezil Hcl | Donepezil Hcl | 128 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 21 |
| Memantine Hcl | Memantine Hcl | 112 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 17 |
| Alendronate Sodium | Alendronate Sodium | 93 | 18 |
| Celecoxib | Celecoxib | 92 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 11 |
| Farxiga | Dapagliflozin Propanediol | 83 | 11 |
| Pregabalin | Pregabalin | 83 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 13 |
| Lorazepam | Lorazepam | 74 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 64 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 55 |
| Ozempic | Semaglutide | 61 | 13 |
| Clonazepam | Clonazepam | 60 | 11 |
| Torsemide | Torsemide | 55 | suppressed |
| Mirtazapine | Mirtazapine | 54 | suppressed |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Sucralfate | Sucralfate | 46 | suppressed |
| Glipizide Er | Glipizide | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Estradiol | Estradiol | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Cefdinir | Cefdinir | 37 | 35 |
| Azithromycin | Azithromycin | 36 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Primidone | Primidone | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 22 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Letrozole | Letrozole | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 26 | 13 |
| Fluconazole | Fluconazole | 25 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 24 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 15 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 11 |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Mercaptopurine | Mercaptopurine | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.52 · 15 records | PFIZER INC. | ABRYSVO, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, Fluad, Flucelvax, Kerendia, LEQVIO, Ozempic, PREVNAR 20, Rybelsus, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error